We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
ForewordFree Access

Induced pluripotent stem cells: opportunities and challenges

    M William Lensch

    † Author for correspondence

    Howard Hughes Medical Institute at Children’s Hospital Boston, MA, USA and Harvard Medical School, Boston, MA, USA and Harvard Stem Cell Institute, 1 Blackfan Circle, Boston, MA 02115, USA.

    Search for more papers by this author

    Email the corresponding author at mathew.lensch@childrens.harvard.edu

    &
    Mahendra Rao

    Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, CA 92008 USA

    Search for more papers by this author

    Published Online:15 Jul 2010https://doi.org/10.2217/rme.10.49
    "Induced pluripotent stem cells: opportunities and challenges." , 5(4), pp. 483–484

    Bibliography

    • 1  Yamanaka S: Identification of factors that generate ES-like pluripotent cells from fibroblast culture. Presented at: 4th International Society for Stem Cell Research. Ontario, Canada, 29 June–1 July (2006).
      Google Scholar
    • 2  Gaines P, Liu R, Park I-H: Research Highlights. Regen. Med.5(4),501–503 (2010).
      Google Scholar
    • 3  Grskovic M, Seidenman K, Dimos JT: Cell programming: jumping back to pluripotency or rewiring fate. Regen. Med.5(4),493–495 (2010).
      Google Scholar
    • 4  Walker J: Disease in a dish: a new approach to drug discovery. Regen. Med.5(4),505–507 (2010).
      Google Scholar
    • 5  Ye Z, Cheng L: Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. Regen. Med.5(4),521–530 (2010).
      CASGoogle Scholar
    • 6  Huang K, Fan G: DNA methylation in cell differentiation and reprogramming: an emerging systematic view. Regen. Med.5(4),531–544 (2010).
      CASGoogle Scholar
    • 7  Lakshmipathy U, Davila J, Hart RP: miRNA in pluripotent stem cells. Regen. Med.5(4),545–555 (2010).
      CASGoogle Scholar
    • 8  West MD, Homayoun V: Back to immortality: the restoration of embryonic telomere length during induced pluripotency. Regen. Med.5(4),485–488 (2010).
      CASGoogle Scholar
    • 9  Flynn P, Yingling J, Shoemaker D: Converging technologies to enable induced pluripotent stem cells in drug discovery. Regen. Med.5(4),489–491 (2010).
      CASGoogle Scholar
    • 10  Rowntree RK, McNeish JD: Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery. Regen. Med.5(4),557–568 (2010).
      CASGoogle Scholar
    • 11  Georgieva BP, Love JM: Human induced pluripotent stem cells: review of the US patent landscape. Regen. Med.5(4),581–591 (2010).
      Google Scholar
    • 12  Carpenter MK, Couture LA: Regulatory considerations for the development of autologous iPS cell therapies. Regen. Med.5(4),569–579 (2010).
      CASGoogle Scholar
    • 13  Smith D: Commercialization challenges associated with induced pluripotent stem cell-based products. Regen. Med.5(4),593–603 (2010).
      Google Scholar
    • 14  Csete M: Translational prospects for human induced pluripotent stem cells. Regen. Med.5(4),509–519 (2010).
      Google Scholar